1 minute read
Our mission
Icon Group’s mission is to deliver the best care possible, to as many people as possible, as close to home as possible. Through a comprehensive end-to-end model, Icon provides the full spectrum of cancer care including haematology, medical oncology, radiation oncology, chemotherapy compounding, pharmacy management and clinical research.
Across the international network Icon saw over 2.5 million patient interactions in 2021 and is on target to move to four million annually by 2023. Icon Group is essential to the healthcare ecosystem and continues to innovate and disrupt the way cancer care is delivered for the benefit of communities globally.
OUR VISION FOR RESEARCH
With over 35 years’ experience, research is part of Icon’s DNA. Icon’s international network of clinicians believe clinical trials are critical to the provision of exceptional cancer care and continue to confidently lead the way in operating Australia’s largest private cancer clinical trials program.
Icon has a long-term commitment to increasing access to clinical trials and emerging treatments. This commitment is backed by international industry partnerships, investment in dedicated research teams and clinical leadership from highly respected researchers and specialists. Research at Icon aims to provide more patients with opportunities previously not available to them by bringing tomorrow’s treatments closer to today.
